Despite advances over the past several decades, the clinical trials enterprise has struggled to meet the needs of an increasingly diverse U.S. population. To help address this issue, a 2023 National Academies workshop sought to identify the expertise and disciplines needed to achieve the aspirations for a transformed clinical trials enterprise by 2030 and enable a workforce that can better support the evolving needs of drug R&D - one that is resilient, culturally aware, anti-racist, and interdisciplinary. The workshop, hosted by the Forum on Drug Discovery, Development, and Translation and Roundtable on Black Men and Black Women in Science, Engineering, and Medicine explored strategies to bolster workforce capacity and challenges and opportunities associated with supporting the next-generation drug R&D workforce.Table of ContentsFront Matter1 Introduction2 Exploring the Future State of the Clinical Trials Workforce3 Examining the Current State of the Clinical Trials Workforce4 Overcoming Barriers to Progress5 Envisioning the Future Landscape6 Scaling and Sustainability of Workforce Programs7 Policies for Workforce Sustainability and Future-Proofing8 Considering A Path ForwardReferencesAppendix A: Workshop AgendaAppendix B: Biographical Sketches of the Workshop Planning Committee, Speakers, and Panelists